Opinion

Video

Newer Combinations for the Treatment of CLL

Author(s):

Yuliya P.L Linhares, MD,Josie Montegaard, MSN, AGPCNP-BC

Dr Linhares discusses newer combination therapies for the treatment of patients with chronic lymphocytic leukemia, highlighting ibrutinib and venetoclax, which is being studied in the CAPTIVATE trial.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Image of man with brown hair.
Related Content
Image of Andy.
July 13th 2025

Finding Comfort and Connection in the Chemo Lounge

Andy Winnegar
During treatment for chronic lymphocytic leukemia and autoimmune anemia, I found relief and encouragement in a caring conversation with my oncology nurse.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Linda Cohen is a survivor of small lymphocytic lymphoma and was diagnosed in 2009. Catch up on all of Linda's blogs here!
July 1st 2025

A Cocktail and the Freedom I Never Expected With Cancer

Linda Cohen
After years off medication, I finally enjoyed a grapefruit cocktail — symbolizing freedom from cancer’s constant shadow and hope for the future.
CURE Talks Cancer podcast
December 31st 2020

The Treatment Journey of a Patient with CLL

Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.
Breyanzi demonstrated a 95.5% response rate among in relapsed/refractory marginal zone lymphoma: © stock.adobe.com.
June 17th 2025

Breyanzi Shows Durable Responses in R/R Marginal Zone Lymphoma

Spencer Feldman
Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a durable safety.
FDA approves new Brukinsa tablet for five blood cancers: © stock.adobe.com.
June 12th 2025

FDA Approves Brukinsa Tablet For Various Blood Cancers

Spencer Feldman
FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as capsules.